Your Neurodegenerative Disease Clinical Trial Partner

ARG provides the commitment and stability to deliver on your neurodegenerative project

We Understand Your Challenges in Neurodegenerative Projects:

  • Does your CRO have strong relationships with investigators, professors, key opinion-leaders and sites?
  • Does your CRO consider the challenges that many neurodegenerative patients face in terms of communication when granting consent?
  • Does your study team consider the number, order, and difficulty of assessment loads for patients struggling with neurodegenerative diseases?
  • Does your CRO take patient dexterity into account when looking at IMP packaging?
We Can Put the Pieces Together

Neurodegenerative diseases such as ALS and dementia are very challenging for patients in clinical trials. As a result, it is imperative that the study teams have experience in, and understanding of, neurodegenerative studies in order to foster patient centricity. All of the stakeholders must be taken into account in order to create a stable project environment.

Trusted by chief investigators at leading sites, ARG’s knowledge and understanding of the US and European regulatory environment and processes means that the trials we manage are largely free from the impediments and duplication of efforts that can be associated with multi-site projects. Our repeated success over time in neurodegenerative studies is rooted in our long-term commitment to knowledge, relationships, patients, and treatments.

“I am not on my own — we are a truly collaborative team that learns from each other continuously. All together we try to make a difference.”

“The ARG mindset is to be an operational extension of the client’s team. We aspire to the end goal just as much as the Sponsor — that vested interest is mutual. Because of this total commitment at all levels of our organization, we are always available to support, assist, and get involved to ensure the task at hand is completed–and to the highest standard at that.”

Janicka Blakemore
Neurodegenerative Project Manager
ARG Specializes In Neurodegenerative Disease CRO Services
10+ YEARS EXPERIENCE IN NEURO-DEGENERATIVE TRIALS
ALL PHASES INCLUDING PROOF OF CONCEPT STUDIES
STRONG, LONG-TERM CONNECTIONS WITH SITES
ACT AS AN EXTENSION OF SPONSOR STUDY TEAM
EXPERIENCE RANGE FROM ALS TO HUNTINGTON’S TO DEMENTIA
ESTABLISHED RELATIONSHIPS WITH THOUGHT LEADERS

ARG Best Practices in Neurodegenerative Trials

Engagement with Partners

  • Allows us to notice details that drive solutions to trial challenges
  • Drives meaningful communication with stakeholders
  • Fosters collaboration and innovation with experts in oncology

Communication Creates Trust ›

Focus on Patients

  • Nurtures relationships with immunology advocacy groups
  • Innovates with our “Study champion” model
  • Understands and addresses human factors

What Patient-Centric Means ›

Tools Foster Visibility

  • Integrates products and platforms seamlessly and efficiently
  • Unifies best-available technologies for each functional area
  • Provides project visibility with near real-time reporting

Visibility Builds Trust ›

Case Study
Neurodegenerative
ARG Rescues Study With Stability,
High Standards and Accessibility

The main issues the Sponsor faced on the project with the original CRO were high turnover, low site support, and subpar deliverables. The challenge was to find an alternative solution, namely, to turn to another organization to rescue the project. The Investigator on site made a specific recommendation based on a past work relationship.